Amgen Inc. (VIE:AMGN)

Market Cap	154.34B +8.6%
Revenue (ttm)	31.30B +10.0%
Net Income	6.57B +88.5%
EPS	12.12 +88.2%
Shares Out	n/a
PE Ratio	23.50
Forward PE	15.06
Dividend	8.52 (2.94%)
Ex-Dividend Date	Nov 21, 2025

Volume	224
Average Volume	62
Open	285.65
Previous Close	289.90
Day's Range	284.05 - 289.85
52-Week Range	230.50 - 307.30
Beta	n/a
RSI	55.24
Earnings Date	Feb 3, 2026

About Amgen

Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company’s principal products include Enbrel for the treatment of rheumatoid arthritis, plaque psoriasis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet’s disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascul...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 1980
• Employees: 28,000
• Stock Exchange: Vienna Stock Exchange
• Ticker Symbol: AMGN

Financial Performance

In 2025, Amgen's revenue was $36.75 billion, an increase of 9.95% compared to the previous year's $33.42 billion. Earnings were $7.71 billion, an increase of 88.53%.

Financial numbers in USD